ClinicalTrials.gg
RecruitingNCT02852928chILD-EUUpdated Sep 21, 2022

European Management Platform for Childhood Interstitial Lung Diseases - chILD-EU Register and Biobank

An observational study in Lung Diseases, Interstitial, Pulmonary Alveolar Proteinosis and Pulmonary Eosinophilia, sponsored by Matthias Griese. Recruiting at 3 sites in 3 countries. Per ClinicalTrials.gov, last updated 2022-09-21.

Primary conditionPulmonary FibrosisRegistry: Lung Diseases, InterstitialReclassifiedWhy we changed it
Registry
Lung Diseases, Interstitial — the first condition term the registry derived for this study.
ClinicalTrials.gg
Pulmonary Fibrosis
Why
  1. The study's listed conditions name Pulmonary Fibrosis, a narrower term within Lung Diseases, Interstitial.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Matthias Griese · Observational

How we know

From the registry’s dates

  • Started Dec 2013; still recruiting 12 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
1,000
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 25 studies in Pulmonary Fibrosis with a site in Germany — 4 open to participants now, 8 under way, 3 of them phase 3. Pulmonary Fibrosis · Germany.

Started
2013
with 1 other
Observational
4 of 25
2 open now
Registered
8th of 25
by date

Among the 25 studies in Pulmonary Fibrosis with a site in Germany, this one is one of 2 that started in 2013, is one of 4 observational ones, and was the 8th registered.

Pulmonary Fibrosis

342 studies on the registry are indexed under Pulmonary Fibrosis; 98 are open to participants now.

Browse Pulmonary Fibrosis studies →

Open to participants now

4 of the 25 studies in Pulmonary Fibrosis with a site in Germany are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 71 Pulmonary Fibrosis studies recruiting now, 41 (58%) set no upper age limit and 4 (6%) stop at 75 or younger; 8 take children under 18; 12 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Pulmonary Fibrosis with a site in Germany, or all of them as a file.
02

Study summary

Generation of a common European database and biobank Continous assessment and implementation of guidelines and treatment protocols Establishment of a large observational cohort of chILD patients Determination the value of outcomes used in child Assess treatment variations used, deliver data from defined protocols and linked outcomes

Read the detailed description

Objective 1: Generation of a common European database and biobank. The existing national programmes to collect data on chILD in three countries (France, Germany, UK) will enable the consortium to swiftly adapt current frameworks to a functionally appropriate pan-European web-based database and biobank. Importantly, compatibility with ongoing United States chILD data base developments will be factored in.

Objective 2: Continuous assessment and implementation of guidelines and treatment protocols. Our Standards Working Group will convene regularly. Initial tasks will establish (a) specific diagnostic pathways, including detailed protocols for gathering clinical information, blood testing, imaging and pathology ("Best Practice Checklist"); (b) international panels of clinicians, geneticists, radiologists and pathologists who will review every diagnosis to quality control the data; and (c) detailed protocols for follow up to generate natural history data.

Objective 3: Recruitment of a carefully characterized cohort of chILD patients. European wide recruitment and interdisciplinary critical peer review of all diagnoses submitted from across Europe is imperative. Each case will be given a diagnosis independently; if no firm diagnosis is possible, we will review the case periodically as new information becomes available. During the first year of the study, clinicians´ decisions according to local practice and outcomes will be independently monitored and assessed.

Objective 4: Determine the value of outcomes used in chILD. We will systematically optimize and clarify the relative weight of a large spectrum of single and composite clinical outcomes (using both clinician and carer scoring), sequential limited chest CT (to minimise radiation exposure), lung function testing, histopathological categorization of lung biopsies, serum markers and genetic tests. Variability, reproducibility and the effects of training on reading images will be investigated.

Objective 5: Assess treatment variations used, deliver data from defined protocols and linked outcomes. This project will analyse in detail treatment and outcomes within and between subjects using data collected. Analysis of the collected data will enable us to support the definition of trial protocols planned in the future.

03

Conditions studied

  • Lung Diseases, Interstitial
  • Pulmonary Alveolar Proteinosis
  • Pulmonary Eosinophilia
  • Pulmonary Fibrosis
  • Respiratory Distress Syndrome, Newborn
  • Child

Keywords

  • ILD; chILD
04

In context

Pulmonary Fibrosis Reclassified

342 studies on the registry are indexed under Pulmonary Fibrosis; 98 are open to participants now.

This study's planned enrollment of 1,000 is above the median of 150 across 118 observational studies indexed under Pulmonary Fibrosis.

Browse Pulmonary Fibrosis studies →

Lead sponsor

Matthias Griese is the lead sponsor of 3 studies on the registry; 1 is open to participants now.

Compared within Pulmonary Fibrosis, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lung Diseases, Interstitial. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

400 prevalent patients with childhood interstitial lung disease (chILD) in Europe 100 incident chILD cases per year

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • all children with suspected or
  • verified diagnosis of ILD or
  • masquerading as ILD and
  • those with rare localized parenchymal lung diseases

Exclusion criteria

Exclusion Criteria:

  • other indication as inclusion criteria
06

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
1,000 participants (estimated)
Target follow-up
10 Years
Patient registry
Yes
07

What researchers measure

Primary outcomes

  1. Included subjects with specific diagnosis

    Number of recruited subjects

    Time frame: 10 years

Secondary outcomes

  1. Survial

    Survival of the participants

    Time frame: 10 years

08

Study locations

3 of 3 sites recruiting
09

References and documents

Publications

  • Griese M, Seidl E, Hengst M, Reu S, Rock H, Anthony G, Kiper N, Emiralioglu N, Snijders D, Goldbeck L, Leidl R, Ley-Zaporozhan J, Kruger-Stollfuss I, Kammer B, Wesselak T, Eismann C, Schams A, Neuner D, MacLean M, Nicholson AG, Lauren M, Clement A, Epaud R, de Blic J, Ashworth M, Aurora P, Calder A, Wetzke M, Kappler M, Cunningham S, Schwerk N, Bush A; the other chILD-EU collaborators. International management platform for children's interstitial lung disease (chILD-EU). Thorax. 2018 Mar;73(3):231-239. doi: 10.1136/thoraxjnl-2017-210519. Epub 2017 Oct 22. PubMed 29056600 ↗

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2013 (actual). Primary completion is estimated for Dec 2028, 180 months after the start.

Of 60 observational studies under Pulmonary Fibrosis, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 111. This study's planned 180 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 29, 2016
First posted
Aug 2, 2016
StartActual
Dec 2013
Primary completionEst.
Dec 2028
CompletionEst.
Dec 2029
Last update
Sep 21, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02852928
Lead sponsor
Matthias Griese
Responsible party
Matthias Griese (Prof. Dr. med., Ludwig-Maximilians - University of Munich) — Sponsor-investigator
First posted
Aug 2, 2016
Start date
Dec 2013
Primary completion
Dec 2028 (estimated)
Completion
Dec 2029 (estimated)
Last update
Sep 21, 2022

Study contacts

Matthias Griese, Prof.
Contact
Matthias.Griese@med.uni-muenchen.de
+49/89/440057871
Katarzyna Michel, Dr. med.
Contact
Katarzyna.Michel@med.uni-muenchen.de
+49/89/440057878
Matthias Griese, Prof.
study chair · Klinikum der Universität München, Dr. von Haunersches Kinderspital

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion